MedPath

Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema

Phase 1
Conditions
Diffuse Diabetic Macular Edema
Interventions
Registration Number
NCT00999791
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Diffuse Macular Edema is the main cause of visual disorders in diabetic patients.

Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse diabetic macular edema for treatment. in this study, we are going to compare the effect of intra vitreal injection of Diclofenac and Bevacizumab in primary treatment of diffuse diabetic macular edema.

Detailed Description

Diffuse Macular Edema is the main cause of visual disorders in diabetic patients.

Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse diabetic macular edema for treatment. in this study, we are going to compare the effect of intra vitreal injection of Diclofenac and Bevacizumab in primary treatment of diffuse diabetic macular edema.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • patients with clinically significant macular edema and diffuse macular edema
Exclusion Criteria
  • any history of focal photocoagulation
  • any prior intra ocular injection
  • history of glaucoma with high pressure
  • history of ophthalmic surgery
  • high rish PDR
  • active PDR

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DiclofenacDiclofenac-
AvastinBevacizumab-
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ophthalmic Research Center

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath